Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 03:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
NCT00643604 · United Therapeutics · PHASE4 · terminated · last registry update 2024-01-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to availability of eligible subjects at center and enrollment competition with other studies.” | – | Registry record, United Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGIR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-20Results posted on the registry: Actelion, Selexipag (NCT04565990)
- 2024-11-12Results posted on the registry: University of Edinburgh, Isosorbide Mononitrate XL (ISMN) + Cilostazol (NCT03451591)
- 2024-11-01Results posted on the registry: United Therapeutics, Treprostinil Inhalation Powder (NCT03950739)
- 2024-10-15Also stopped (terminated): Duke University, Inhaled Iloprost (NCT02170519)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-08-20Results posted on the registry: Actelion, JNJ-67896049 (NCT04435782)
- 2024-07-30Results posted on the registry: Liquidia Technologies, Inc., LIQ861 Inhaled Treprostinil (NCT03399604)
- 2024-06-21Also stopped (terminated): Actelion, Selexipag + Placebo (NCT03689244)
- 2024-06-18Also stopped (terminated): United Therapeutics, treprostinil diethanolamine (NCT00848107)
- 2024-05-17Also stopped (withdrawn): National Cancer Institute (NCI), Iloprost + Placebo Administration (NCT05411107)
- 2024-05-08Results posted on the registry: Actelion, Selexipag + Placebo (NCT03942211)
- 2024-05-08Also stopped (terminated): Actelion, Selexipag + Placebo (NCT03942211)
- 2024-04-05Phase 3 first posted: AOP Orphan Pharmaceuticals AG, preservative-free parenteral treprostinil (NCT06350032)
- 2024-04-02Results posted on the registry: Duke University, Iloprost and nitric oxide administration (NCT03044314)
- 2024-04-02Also stopped (terminated): Duke University, Iloprost and nitric oxide administration (NCT03044314)
- 2024-03-05Results posted on the registry: United Therapeutics, IV Remodulin + Placebo (NCT02261883)
- 2024-03-05Also stopped (terminated): United Therapeutics, IV Remodulin + Placebo (NCT02261883)
- 2024-01-03Also stopped (terminated): United Therapeutics, treprostinil (NCT00439946)
- 2023-12-19Also stopped (withdrawn): United Therapeutics, treprostinil sodium + Placebo (NCT01884038)
- 2023-12-18Results posted on the registry: United Therapeutics, Inhaled treprostinil solution (NCT03794583)
- 2023-12-12Also stopped (terminated): University Hospital, Grenoble, Treprostinil iontophoresis (NCT03654989)
- 2023-11-24Results posted on the registry: United Therapeutics, Inhaled treprostinil solution + Placebo solution (NCT03496623)
- 2023-11-24Also stopped (terminated): United Therapeutics, Inhaled treprostinil solution + Placebo solution (NCT03496623)
- 2023-10-18Results posted on the registry: Bastiaan Driehuys, Hyperpolarized 129Xenon gas (NCT03367312)
- 2023-10-04Results posted on the registry: Eli Lilly and Company, Sodium Citrate + Treprostinil (NCT05067270)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision